老年血液系统恶性肿瘤的综合治疗策略
该系列文章综述了过去十年老年血液系统恶性肿瘤的治疗选择与综合管理考虑,聚焦淋巴瘤、急性白血病、慢性白血病和多发性骨髓瘤。文章指出欧洲所有血液肿瘤诊断中位年龄为69岁,75岁以上患者总体生存较差,尤其急性白血病。未来策略包括提高老年患者临床试验入组率和将患者报告结局纳入日常临床实践。
要点
- 欧洲血液肿瘤诊断中位年龄69岁,发病率随年龄增长,75-99岁达峰(霍奇金淋巴瘤和急性淋巴细胞白血病除外)。
- 75岁及以上血液肿瘤患者总体生存普遍较差,尤其急性白血病。
- 需理解老年患者结局异质性、治疗挑战及衰弱与合并症管理以更好应对疾病负担。
核心结论
- 老年血液系统恶性肿瘤治疗需综合考虑疾病异质性、衰弱和合并症,未来应提高老年患者临床试验入组并纳入患者报告结局以实现个体化医疗。
研究设计与样本
- 系列文章,综述过去十年关于老年血液系统恶性肿瘤治疗选择和综合管理考虑的知识。
主要发现
- 欧洲所有血液肿瘤诊断中位年龄为69岁,发病率随年龄增长至75-99岁达峰,霍奇金淋巴瘤和急性淋巴细胞白血病例外。
- 75岁及以上血液肿瘤患者总体生存普遍较差,尤其急性白血病。
临床怎么用
- 临床应关注老年患者的衰弱和合并症管理,并考虑提高老年患者临床试验入组率及纳入患者报告结局测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haematological malignancies are a heterogeneous group of diseases with diverse incidence. In Europe, the median age at diagnosis across all disease entities is 69 years. Incidence generally increases with age, reaching a maximum at 75-99 years, with the notable exceptions of Hodgkin lymphoma and acute lymphocytic leukaemia. Overall survival for patients aged 75 years and older with haematological malignancies is generally poor, particularly for acute leukaemias. Understanding the heterogeneity in outcomes for haematological malignancies, treatment challenges, and management of frailty and comorbidities among older patients could help physicians to better address the haematological cancer burden and mortality in ageing populations. The aim of this Series paper is to provide an updated overview of the knowledge accumulated over the past decade regarding treatment options and broader management considerations in older adults with haematological malignancies, focusing on the most common entities encountered across lymphoma, acute leukaemia, chronic leukaemia, and multiple myeloma disease categories. Future strategies, such as increasing enrolment rates of older adults in clinical trials and incorporating patient-reported outcome measurements in daily clinical practice, will assist in providing more individualised health care.
引用
- Cordoba R, Eyre TA, Klepin HD, et al. A comprehensive approach to therapy of haematological malignancies in older patients. Lancet Haematol. 2021. PMID: 34624238. doi:10.1016/S2352-3026(21)00241-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。